KalVista Pharmaceuticals (KALV) Competitors $10.87 -0.53 (-4.65%) Closing price 04:00 PM EasternExtended Trading$11.37 +0.50 (+4.60%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KALV vs. CGON, AGIO, HRMY, IDYA, BLTE, JANX, GLPG, TARS, VERA, and AAPGShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include CG Oncology (CGON), Agios Pharmaceuticals (AGIO), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), Janux Therapeutics (JANX), Galapagos (GLPG), Tarsus Pharmaceuticals (TARS), Vera Therapeutics (VERA), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. CG Oncology Agios Pharmaceuticals Harmony Biosciences IDEAYA Biosciences Belite Bio Janux Therapeutics Galapagos Tarsus Pharmaceuticals Vera Therapeutics Ascentage Pharma Group International KalVista Pharmaceuticals (NASDAQ:KALV) and CG Oncology (NASDAQ:CGON) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, community ranking, valuation, earnings, analyst recommendations and media sentiment. Do analysts prefer KALV or CGON? KalVista Pharmaceuticals currently has a consensus price target of $23.80, indicating a potential upside of 118.95%. CG Oncology has a consensus price target of $65.14, indicating a potential upside of 159.53%. Given CG Oncology's higher probable upside, analysts clearly believe CG Oncology is more favorable than KalVista Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14CG Oncology 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has preferable earnings and valuation, KALV or CGON? CG Oncology has higher revenue and earnings than KalVista Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$126.64M-$3.64-2.99CG Oncology$684K2,790.28-$48.61MN/AN/A Do insiders & institutionals have more ownership in KALV or CGON? 26.6% of CG Oncology shares are held by institutional investors. 10.5% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to KALV or CGON? In the previous week, KalVista Pharmaceuticals had 5 more articles in the media than CG Oncology. MarketBeat recorded 10 mentions for KalVista Pharmaceuticals and 5 mentions for CG Oncology. KalVista Pharmaceuticals' average media sentiment score of 0.79 beat CG Oncology's score of 0.49 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is KALV or CGON more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to CG Oncology's net margin of -10,642.98%. CG Oncology's return on equity of -18.97% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -103.92% -88.06% CG Oncology -10,642.98%-18.97%-15.36% Does the MarketBeat Community prefer KALV or CGON? KalVista Pharmaceuticals received 323 more outperform votes than CG Oncology when rated by MarketBeat users. However, 91.30% of users gave CG Oncology an outperform vote while only 74.78% of users gave KalVista Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKalVista PharmaceuticalsOutperform Votes34474.78% Underperform Votes11625.22% CG OncologyOutperform Votes2191.30% Underperform Votes28.70% SummaryCG Oncology beats KalVista Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$537.17M$7.20B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-2.996.1524.9519.22Price / SalesN/A187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book2.246.447.334.28Net Income-$126.64M$139.03M$3.18B$247.04M7 Day Performance5.02%-5.52%-4.42%-4.36%1 Month Performance17.90%-8.56%-6.07%-5.60%1 Year Performance-23.13%-14.59%11.42%3.38% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals4.7803 of 5 stars$10.87-4.6%$23.80+119.0%-19.4%$537.17MN/A-2.99100Upcoming EarningsShort Interest ↓High Trading VolumeCGONCG Oncology1.3435 of 5 stars$26.78-3.8%$65.14+143.3%-41.2%$2.04B$200,000.000.0061AGIOAgios Pharmaceuticals4.4258 of 5 stars$35.47+0.7%$56.57+59.5%+10.1%$2.03B$36.50M3.13390Gap UpHRMYHarmony Biosciences4.6539 of 5 stars$34.20-1.1%$53.67+56.9%+5.4%$1.95B$582.02M16.21200Earnings ReportAnalyst RevisionIDYAIDEAYA Biosciences4.0385 of 5 stars$21.33-2.4%$53.58+151.2%-55.5%$1.87B$7M-6.4680Gap UpBLTEBelite Bio2.5218 of 5 stars$56.52-0.8%$96.33+70.4%+23.0%$1.80BN/A-50.9210Upcoming EarningsNews CoverageJANXJanux Therapeutics3.3549 of 5 stars$33.58-6.7%$89.90+167.7%-31.0%$1.76B$13.05M-28.7030Earnings ReportAnalyst ForecastNews CoverageGLPGGalapagos0.1973 of 5 stars$26.56-0.7%$26.75+0.7%-25.7%$1.75B$275.65M0.001,123Gap UpTARSTarsus Pharmaceuticals2.1314 of 5 stars$45.54-4.8%$56.00+23.0%+20.4%$1.74B$17.45M-11.9550Earnings ReportAnalyst RevisionVERAVera Therapeutics2.5067 of 5 stars$27.19-4.9%$65.44+140.7%-39.1%$1.72BN/A-10.4240Earnings ReportAnalyst RevisionAAPGAscentage Pharma Group InternationalN/A$19.63-7.3%N/AN/A$1.71BN/A0.00600Quiet Period ExpirationGap Up Related Companies and Tools Related Companies CGON Alternatives AGIO Alternatives HRMY Alternatives IDYA Alternatives BLTE Alternatives JANX Alternatives GLPG Alternatives TARS Alternatives VERA Alternatives AAPG Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KALV) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts